# Duloxetine for the Treatment of Generalized Anxiety Disorder

> **NCT00803361** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 210 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Duloxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00803361
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2010-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803361, "Duloxetine for the Treatment of Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00803361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*